Thus, since the trend in medical care is moving toward more personalized pharmacotherapy, the blockade of peripheral Y2-receptors could be targeted for the treatment of the obesity accompanied with elevated noradrenergic NPY levels (e.g., during stress or genetic NPY overexpression) in energy rich environment. The gene discussed is NPY; the disease is obesity due to melanocortin 4 receptor deficiency.